Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Targeted Anticancer Therapies Congress 2022: Programme

ESMO-TAT-2022-1000x250

The TAT 2022 programme is online!

Access the online programme

Learning objectives

The development of novel anticancer agents in hypothesis-testing trials can transform our understanding of malignancies and impact clinical care. The TAT meeting is a meeting focused on early clinical trials and has been described as ‘The home of phase I in oncology’. This meeting will be entirely dedicated to improving the conduct of early anti-cancer clinical trials, with presentations, discussions and educational reviews and workshops highlighting emerging pre-clinical and clinical data, as well as defining optimal methodologies for early clinical trials.

TAT 2022 will bring together experts in anticancer drug discovery and clinical development, translational scientists, and regulators in a unique forum to highlight recent advances and new data, whilst promoting collaboration and knowledge-sharing in a bench-to-bedside approach. In addition, there are opportunities for new investigators and faculty to present their work and interact with experts, and mentoring opportunities through workshops.

In Keynote lectures, Educational sessions, Workshops, Scientific Sessions and Poster exhibition based on abstracts selection, attendees will be able to update their knowledge on:

  • Drug discovery and development of oral immunomodulatory agents, bispecifics and T-cell engagers
  • Molecular imaging technologies
  • Pre-clinical testing to identify effective combination strategies
  • Immune based therapies including ADCs, cytokines, multitargeted agents
  • Breakthroughs in cellular therapies
  • Implementing synthetic lethality approaches in drug development
  • Precision medicine including new protein degraders and new kinase inhibitors
  • Clinical trial adaptations during Covid19

Accreditation

ESMO-MORA: The TAT 2022 Congress programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.

Webcasts

The congress webcasts will include all the sessions of the official programme, where speaker permission is granted, and will be available on this website and on OncologyPRO for ESMO members.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings